Cost, not adherence, main barrier to antiretroviral treatment in Africa Comment 30 January 2013 Pages: 4 - 4
Early initiation of irbesartan provides maximum cost benefits Clinical study 30 January 2013 Pages: 5 - 5
Cost savings, improved productivity expected with migraine programme Media release 30 January 2013 Pages: 6 - 6
Inhaled nitric oxide worth it for neonatal pulmonary hypertension Clinical study 30 January 2013 Pages: 8 - 8
Paediatric psychotropic drug use on the rise in The Netherlands Clinical study 30 January 2013 Pages: 8 - 8
Assessing quality of care for MDD in England, Germany, Switzerland Clinical study 30 January 2013 Pages: 9 - 9
HRQOL predictive of survival in breast cancer treatment Clinical study 30 January 2013 Pages: 10 - 10
QOL outcomes similar with cisplatin + paclitaxel, cisplatin alone Clinical study 30 January 2013 Pages: 10 - 10
Second-generation antipsychotics: QOL effect in schizophrenia Clinical study 30 January 2013 Pages: 10 - 10
Gilead's antiretroviral combo available at not-for-profit price News item 30 January 2013 Pages: 11 - 11
Market growth tipped for IBD, neuropathic pain therapies by 2009 News item 30 January 2013 Pages: 11 - 11
WHO takes action to control leishmaniasis in Afghanistan Media release 30 January 2013 Pages: 11 - 11